Welcome
Support Centre
17 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
To evaluate surgical treatments of great saphenous vein insufficiency: Endovenous LAser treatment versus Crossectomy and Stripping
ISRCTN ISRCTN18322872
ClinicalTrials.gov identifier
Public title To evaluate surgical treatments of great saphenous vein insufficiency: Endovenous LAser treatment versus Crossectomy and Stripping
Scientific title A prospective, Randomised, two-centre study to evaluate surgical treatments of great saphenous vein insufficiency: Endovenous LAser treatment versus Crossectomy and Stripping
Acronym RELACS
Serial number at source RELACS v1.7 (10.09.2004)
Study hypothesis Clinical recurrence is less frequent 2 years after endovenous laser treatment with a 11% difference compared with high ligation and stripping
Lay summary Not provided at time of registration
Ethics approval Medical Council of the Saarland (Ärztekammer des Saarlandes) Saarbrücken, Germany approved on 29th July 2004, identification-no. 98/2004
Study design Randomised controlled trial
Countries of recruitment Germany
Disease/condition/study domain Great saphenous vein insufficiency
Participants - inclusion criteria 1. Great saphenous vein (GSV) insufficiency with saphenofemoral incompetence and reflux at least down to the knee level
2. Chronic venous insufficiency and/or symptoms caused by GSV incompetence and/or severe clinical findings at risk of varicose vein bleeding, thrombophlebitis or deep vein thrombosis
3. Age 18 – 65 years (at randomisation)
4. Performance status according to American Society of Anesthesiology (ASA) I-II
Participants - exclusion criteria 1. Previous surgical interventions in the groin area with the exception of inguinal herniotomy
2. Anterior or posterior accessory vein incompetence
3. Small saphenous vein insufficiency requiring treatment at the same limb
4. Acute deep venous thrombosis or postthrombotic syndrome
5. Known thrombophilia associated with a high risk of thromboembolism
6. Arterial occlusive disease > Fontaine IIA and/or ankle-brachial index below 0.8
7. Active malignancy (diagnosed during the past 5 years)
8. Poor compliance or missing ability to understand the study related procedures
9. Females pregnant or nursing
Anticipated start date 01/09/2004
Anticipated end date 31/03/2007
Status of trial Completed
Patient information material
Target number of participants 400
Interventions Group A : Endovenous Laser Treatment (EVLT): EVLT of the great saphenous vein is performed with an 810 nm Diode laser (bare fibers) using Seldinger's technique ultrasound guided under tumescent local anaesthesia. The energy dose is intended to be 20 J/cm² delivering 20 W laser power. The additional phlebectomy of side branches is allowed.

Group B : High Ligation (Crossectomy) and Stripping (HLS): Standard surgical procedures are performed, consisting of transection of all groin tributaries, flush ligation of the saphenofemoral junction with non-resorbable sutures and neoreflux protection with a continuous stump suture, followed by invagination stripping of the great saphenous vein just below knee under tumescent local anaesthesia. The additional phlebectomy of side branches is allowed.
Primary outcome measure(s) Recurrent varices after surgery (REVAS) evaluated at 12 and 24 months follow up visit.
Secondary outcome measure(s) 1. Duplex recurrence
2. Side effects
3. Homburg Varicose Vein Severity Score
4. Chronic Venous Insufficiency Questionnaire
5. Venous Refilling time (DPPG)
6. Patients' satisfaction is measured using visual analogue scale based questionnaires

Follow-up visits are scheduled in the first postoperative week (side effects), at 3 months [side effects, Homburg Varicose Vein Severity Score (HVVSS), Chronic Venous Insufficiency Questionnaire (CIVIQ), Venous refilling time (DPPG), patient's satisfaction], at 12 months [Duplex recurrence, HVVSS, CIVIQ, DPPG, patient's satisfaction] and at 24 months (Duplex recurrence, HVVSS, CIVIQ, DPPG, patient's satisfaction)
Sources of funding Investigator initiated and funded (Germany)
Trial website
Publications 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21931012
Contact name Dr  Knuth  Rass
  Address Department of Dermatology, Venerology and Allergology
The Saarland University Hospital
Kirrberger Straße
  City/town Homburg
  Zip/Postcode 66421
  Country Germany
Sponsor The Saarland University Hospital (Germany)
  Address Department of Dermatology, Venerology and Allergology
c/o Knuth Rass MD
Kirrberger Straße
  City/town Homburg
  Zip/Postcode 66421
  Country Germany
  Sponsor website: http://www.uniklinikum-saarland.de
Date applied 23/04/2011
Last edited 27/09/2011
Date ISRCTN assigned 19/05/2011
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central